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High teclllwlogy malu!s it possible for large 1tI£dicaL centers to keep
up with physicians' demands for rapid, accurate test resmts. See
story, page 10.
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A recently revived experimental screening procedure
can detect some birth defects at least six weeks earlier
than amniocentesis, allowing problems to be diagnosed
in the first, rather than second, trimester of pregnancy.
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Laboratory Medieine
Physicians often find it cheaper to perform lab tests in
their offices, yet they also have to worry about not
sacrificing quality for the salke of profit or expediency;
several laboratory medicine specialists comment on
these dilemmas, address the high cost and short-life of
high technology, and describe their research.
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A protein found in most organisms - from bacteria to
humans - turns out to be a member of a family known
as the heat shock proteins. Having sequenced its gene
and found some unusual features - scientists would like
to know how the protein, ubiquitin, protects cells against
stress.

Interferons on Trial
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At Washington University School of Medicine, the pro
tein interferon is helping some patients with kidney
cancer and wart-like growths on the larynx. It may also
be useful in the fight against childhood leukemia.
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iabetics - even those
who appear to keep
their blood sugar level s
well-controlled - can be
plagued by side effects of their
disease. Damage to peripheral
nerves and organ s such as the
kidney, together with growth of
new blood vessels in the eye,
are among the leading causes
of diabetes-induced disability.
But a group of new drugs, cur
rently in clinical trials, may
prevent potentially lethal
developments.
Glucose can be metabolized
in several ways, leadi ng to the
formation of various end prod
ucts including the sugar called
sorbitol. Although all persons
possess the enzyme capable of
changing gJucose into sorbitol,
non-diabetics have low levels
of sorbitol because the ir glu
cose level s are low. However,
diabetics with high blood glu
cose levels may convert up to
30 percent of the glucose to
sorbitol.
Unfortunately, sorbitol isn't
easily excreted by cells, and
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scientists think that it - or
metabolic imbal ances asso
ciated with it - causes the
Ii tany of ilis that can plague
even the well-controlled diabe
tic. So reduc ing or preventing
the activity of the enzyme
catalyzing the glucose-to
sorbitol reaction may reduce
the inc idence of ti ssue damage.
Several drug companies are
preparing to conduct human
tests of drugs called aldose
reductase inhibitors (ARls).
These drugs (Sorbinil and Tol
restat are the most-studied)
prevent formation of sorbitol.
But there hasn't been an animal
model in which diabetes
caused blood vessel changes,
equivalent to those in human
diabetics, can be induced read
ily to permit documentation of
ARl s' specific effects. Such a
model has been developed by
Joseph R. Williamson, M.D.
,58, professor of pathology at
Washington University. New
blood vessels formed in the
skin of diabetic laboratory ani
mals show the same marked
increase in permeability as ves
sels in human diabetics.
Williamson says that hi s ani
mal model enables specific
changes induced by the dia
betic milieu to be documented
and studied: "The most charac
teristic functional abnormality
in human diabetic vascular di s
ease," says Williamson, "is
that the blood vessels become
leaky, so that the serum pro
teins leak out of the vessels and
into the tissue. You see this
most dramatically in the eyes
of poorly controlled diabetics.
They develop proliferative
retinopathy - formation of
new blood vessels, which are
especially leaky - in the eye.
But there's never been an ani
mal model in which you could
duplicate thi s phenomenon.

And it's been diffic ult to show
permeability changes in the
blood vessels, or structural
changes.
"There are an incredible
number of metabolic and hor
monal imbalances in diabe
tics," Williamson continues,
"and if you don't have some
identical functional equivalent
in an animal model, then it's
virtually impossible to sort out
which are important and which
aren't. We dec ided to look at
the role of sorbitol metabol ism
with thi s model. We tested the
ARIs and found that they com
pletely prevented the increase
in vascular permeabil ity."
Another contributing factor
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to diabetes-induced complica
tions appears to be sex hor
mones. Pre-pubertal children,
even those with poorly control
led blood sugar levels, are
spared diabetes' side effects
until after puberty.
Williamson was puzzled
about how to reconcile these
data until he remembered that
the sorbitol-creating enzyme
was first discovered in the male
re productive tract. "It's reason
able that this enzyme would be
modulated by sex steroids,
particularly androgens such as
testosterone," he says. "This
may explain why chjldren are
spared the complications of
diabetes and suggests that tight
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Joseph Williamson induces new blood vessels to form in rats by
slipping a piece ofpolyester fabric under the skin. The polyester
fibers plus collagenfibersform aframeworkfor new vessels,
which here appear as circles. Using this technique, Williamson
compares vesselformation in healthy and diabetic animals.
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blood sugar control may not be
so critical before pUberty. After
puberty, ARls may be particu
larly useful in preventing
complications. "
In preliminary tests, Tolres
tat has not caused worrisome
side effects, but Sorbinil has
been implicated in serious
reactions in a few persons. To
Williamson, this means that
care needs to be exercised, just
as with any drug. "Some per
sons can't take a common phar
macologic agent like aspirin,
either, but it doesn't mean it
shouldn't be used . It just means
that we have to use caution,
just as we do with any drug
that's potentially risky."
Charles Kilo, M.D. '59, clin
ical associate professor of med
icine at Washington University,
is cooperating in ARl clinical
trials being conducted at
Barnes and Children's hos
pitals. He heads the Kilo
Foundation, which supports
Williamson's research among
nearly 20 projects annually
funded from its $600,000
budget.
"An animal model such
as the one developed by Dr.
Williamson, exhibiting
changes similar to what goes
on in humans, is a big step for
ward in testing hypotheses
about the mechanism of blood
vessel and nerve injury," says
Kilo. "And the aldose reduc
tase inhibitors could be the
miracle for the diabetic popula
tion that insulin's introduction
was in 1921. If they delay or
prevent blood vessel and nerve
damage, there is the potential
to greatly reduce the severity of
disease in the eye, nerves and
kidneys. This could mean a
savings of about $[0 million
annually in health care and
productivity." •
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ernard Becker, M.D.,
professor and head of
the Department of
Ophthalmology, has received a
$30,000 grant from Research
to Prevent Blindness (RPB), a
voluntary organization com
mitted to the financial support
of eye research.
The award is part of an over
all 20 percent increase in
RPB's nationwide support of
eye research, Becker notes, and
comes at a time when federal
budget cuts are causing con
cern for the continuity of medi 
cal research . During the past
27 years, the Department of
Ophthalmology has received
$293,900 in RPB funds. ''The
significance of these grants
cannot be overstated," Becker
said . "They provide scientific
freedom, and their impact is
felt at every level of oUI re
search program ."
Washington University has
one of the world's largest re
search programs devoted to
ophthalmology and visual
science. On-going research
projects include studies of
glaucoma, ocular manifesta
tions of diabetes, abnormal
retinal biochemi stry and other
eye di seases. The university is
one of more than 50 medical
institutions across the country
whose eye research programs
are assisted by annual grants
from RPB. •
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Gerald Medoff, M.D.
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technique that disarms
a pathogenic fungus
may open the door to
vaccines against disease
causing microorganisms that
change form when they enter
the body.
A team of researchers from
the Medical Mycology Center
reported recently in Science
that a chemical called PCMS *
prevents the thread-shaped His
/oplnsma capsulalUm from
changing into single-cell
yeasts. The fungus causes his
toplasmosis, a respiratory in
fection that strikes an estimated
500,000 Midwesterners each
year. It normally changes shape
when its threads - mycelia 
move from soil as dust into the
warmer environment of the
lungs.
Since only the yeast form
causes disease, PCMS renders
the fungus innocuous. But it
doesn't prevent it from provok
ing an immune response.

Therefore, inoculations of
chemically treated mycelia pro
tect against future infections
with virulent H. capsulalUm, at
least in mice, the subjects of
the Washington University ex
periments.
PCMS changes H. capsula
tum permanently, affecting
both the treated cells and their
progeny, presumably by alter
ing a gene that directs some
crucial stage in the mycelium
to-yeast transition . "We don't
know the mechanism , but we
are following up on that," says
Gerald Medoff, M.D. , profes
sor of medicine and head of the
division of infectious diseases.
" If the transition depended on a
plasmid - an extra-chromo
somal piece of DNA - and
PCMS eliminated that plasmid,
that might be one mechanism.
Or PCMS might cause a chro
mosome to rearrange itsel f."
The altered fungus itself
probably will not become a
vaccine because inoculation
against the usually benign his
toplasmosis seems unneces
sary. However, it could serve as
a model in the development of
other vaccines. ''There are
many parasites, such as the
protozoan that causes malaria,
that have a phase in a vector,
such as a mosquito, and then
convert to another phase when
they affect humans. So if one
could prevent conversion from
one phase to another, it might
be analogous to what we saw
withH. capsulaturn," says
Medoff.
*parachloromercuriphenyl
sulfonic acid
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Shirley Sahrmann shows runner Jennifer Shifrin how to properly
perform lower abdominal exercises.
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hirley Sahrmann, Ph .D.,
associate director for re
search for the program
in physical therapy and assis
tant professor in neurology and
physical therapy, has received
three of the country's foremost
honors in physical therapy.
The American Physical
Therapy Association selected

S
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Sahrmann to receive the
Mari an Williams Award for
Research in Physical Therapy,
and also named her a Catherine
Worthingham Fellow. The Uni
versity of Southern California's
physical therapy department
chose Sahrmann to deliver its
1986 Viola Robins Lecture.
The Marian Williams Award
cites Sahrmann for leadership
in physical therapy research,
and for contributions that have
helped bridge the gap between
animal and human research in
the neurosciences.
Sahrmann is one of only six
recipients of the award, first

presented in 1965 to recognize
individuals who have per
formed sustained and out
standing basic, clinical andlor
educational research pertaining
to physical therapy. The award
commemorates Marian Wil
liams, Ph.D., whose profes
sionallife was dedicated to the
promotion of physical therapy
through teaChing, writing and
research.
The APTA's selection of
Sahrmann as a Catherine
Worthingham Fellow recog
nizes her for national leader
ship in advancing the science,
education and clinical practice
of physical therapy. The fellow
ship was first awarded to for
mer APTA president Catherine
Worthingham in 1982.
Sahrmann is the second dis
tinguished health sc ientist to be
chosen as Viola Robins Lec
turer at the University of
Southern California. Viola
Robins had served as director
of the department and asso
ciate clinical professor of phys
ical therapy. In her lecture,
Sahrmann addressed classifica
tion, the categorizing of
patients by specific muscle im
balance problems in order to
ensure more effective therapy.
Sahrmann first joined Wash
ington University in 1959 as a
staff physical therapist at the
School of Medicine's Irene
Walter Johnson Rehabilitation
Institute. In addition to her cur
rent appointments, she serves
as an instructor in physiology
at the School of Medicine. She
received doctoral and master 's
degrees in neurobiology, as
well as a bachelor's degree in
physical therapy, from Wash
ington University. •
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"Neural

Regenera
tion: Bridging the
Gaps," a feature in
the Fall 1984 issue of Outlook,
described Washington Univer
sity scientists' research on why
brain and spinal cord nerve
cells fail to repair themselves
after injury. One area being
investigated by Gerald
Fischbach's group concerns the
growing nerve tip and its influ
ences on the muscle it inner
vates. They know that where
the nerve touches the muscle,
clusters of acetylcholine recep
tors assemble. (These receptors
enable the muscle to respond to
the neurotransmitter acetyl
choline by contracting.) But
they didn't know whether the
receptor clustering was due to
formation of new receptors, or
whether the nerve caused pre
existing receptors to migrate.
Becau se of some recent
evidence gathered by David
Harris, Fischbach suspects that
the nerve tip causes new recep
tor subunits to be synthesized:
"The receptor molecule is very
complex," explains Fischbach.
"It's made up of four subunits.
David has been using recom
binant DNA probes to measure
the capacity of the muscle to
synthesize receptor subunits.
Our preliminary data suggests
that that's probably increased,
an effect of the growing nerve
tip on the muscle."
Postdoctoral fellow Lorna
Role and predoctoral student
Richard O'Brien found that
nerve has a powerful effect on
muscle: Receptor clusters on
the muscle are within a few
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microns of the growing nerve
tip. Says Fi schbach : "That's a
very high incidence. If you
look anywhere else along the
course of the nerve, the inci 
dence is much lower. And that
leads us to believe that there's
something very special about
the advancing nerve tip."
Another former student, Ted
Usdin , scored an impressive
coup. He was able to purify
a glycoprotein - a sugar
containing protein - from ex
trac ts of chick brain . Using a
protocol developed several
years ago, Usdin added several
new purification steps "and
ended up with a molec ule
purified to homogeneity," says
Fi schbach, "about a million
fold purification, which is a tre
mendous feat. Ted found that
when this glycoprotein was
added to muscle fibers in cul
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ture, it promoted the formation
of rece ptor clusters. "
Now, the question to be
answered is, is this molecule
what growing nerve tips
secrete to induce the receptor
clusters? Postdoctoral fellow
Doug Falls hopes to answer
this question by making anti
bod ies to the glycoprotein .
"Once we have antibodies,"
says Fi schbach, " we' ll see if
the glycoprotein is located
in the growing nerve tip and
if we can use them to block
its effec ts."
Answers to such questions
may prove a boon to clinic ians
trying to treat patients with de
vastating neurologica l condi
tions such as myasthenia gravis
or Alzheimer's disease.
'There's a long list of possible
causes of a disorder like
Alzheimer's di sease," explai ns
Leonard Berg, M.D. , director

of the Alzheimer 's Di sease Re
sea rch Center at Washington
Uni ver,ity. "We don't have
enough background informa
tion to narrow the li st and
focus on (lne or two possible
causes.
" It 's sensible to look for
ways brain cell s handle injury
and adapt to survive and main
tain functi on. And it's logical
to assume th at brain cells will
fall back to the basic mecha
ni sms of growth and develop
ment. Hopefull y, those basic
biologica l principles ca n be
studied in relation to a disease
like Al zheimer's, to give us
some means of palli ating the
disorder and reducing symp
toms until the future, when
we find a cure. "
Gerald Fischbach, M.D. , is
head of Anatomy and
Neur(lbiology.
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A microscopic view ofa chick neuron (righJ) and a muscle fiber (leli) in culture. A process has grown
out of the body ofthe neuron andforkRd over thefiber.lnformatwn, ill theform ofchemical signals,
can pass betweell the two cells at such contm:ts, which are called synapses.
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Clot - Hl'tHh
he layer of cells lining
blood vessel s plays a
key role in repair and
disease processes. The endo
thelium, as it's called, consists
of a single layer of ce ll s which,
under normal conditions, stays
smooth . Any roughness or
irregul arity attracts blood com
ponents that lead to the forma
tion of clots.
Yet when blood vessels give
off new branches or repair
themselves, these lining cell s
must divide. And in diseases
such as atherosclerosis, what
ever keeps these lining cells a
smooth layer stops working or
is overpowered with the devel
opment of an atheroma - a
ma ss inside the blood vessel
that becomes calcified over
time, eventually blocking it.
Researchers have been
struggling for years to lea rn
how blood vessels repair them
selves and grow, and how these
normal processes go awry
when conditions like athero
mas occur. Now, th anks
to research performed at Wash
ington University, there are
some clues.
Thomas Deuel's group has
found a new protein in en
dothelial cells. Thi s protein is
kin to one on which Deuel has
worked for years, a protein
called platelet-derived growth
factor (PDGF). When sec reted
into blood, PDGF attracts
blood cells and other blood
components to the area , and it
stimulates cell divi sion.
The new protein, which is
structurally simil ar to one of
the polypeptide chains com
pri sing PDGF, is manufactured

T
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Atheromas, like the one in this drawing, form after the disruption
ofnormal processes thal repair the linings ofblood vessels.
by the same gene coding for
PDGF molecules, report Deuel
et al. in a recent issue of
Science, Furthermore, Deuel
discovered that this new pro
tein could be found in much
higher levels in actively divid
ing endothelial cells but not in
non-dividing cells. Thus, it
may playa key role in normal
repai r processes, and it may be
implicated in diseases like
atherosclerosis.
"The gene for this PDGF
like protein has been cloned,"
says Deuel, professor of medi
cine and biological chemistry
and director of hematology/on
cology, "a nd we have cloned a
piece of the gene from en
dothelial cells. We have also
developed antibodies to the
protein. With antibodies and
the DNA probe, we hope to go
back and see under what condi

6

tions the gene is expressed."
Using the protein-specific an
tibodies and the DNA probe,
Deuel's team will examine le
sions in the blood vessel wall
and try to correlate anatomical
changes with the presence of
the protein.
'There seems to be a sort of
cascade of events that occurs in
endothelial cells," summarizes
Deuel, M.D., director of the
Marilyn Fixman Cancer Center
at Jewish Hospital. "On the one
hand, these events should lead
to a normal regeneration or re
pair of blood vessels that have
been injured. On the other
hand, in tumor growth or ath
erosclerosi s, those events are
exaggerated or not under the
usual regulation and thus con
tribute to the abnormal situa
tion. But how? That's the
question we're trying to
answer." •
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he Division of Urologic
Surgery has dedicated
its library in honor of
Elwin R. Smith and the
Urologic Research Foundation .
Smith, a St. Louis insurance
executive, established the
Urologic Research Foundation
in 1979 to encourage and sus
tain research in urologic disor
ders. Since its beginning, the
non-profit organization has
raised almost a half million
dollars, primarily through pri
vate individual sources.
'The Division of Urologic
Surgery owes a great deal of
gratitude to the organizers and
supporting members of the
Urologic Research Founda
tion," says William 1. Cata
lona, M.D., professor and chief
of the Division of Urologic Sur
gery. "At a time when gov
ernmental funding of medical
research has been reduced
across the board, funding for
research in urology has been
stripped to the bone.
"We have been touched by
the tremendous support we
have received from Elwin R.
Smith and the other founders
and members of the founda
tion," he adds. "We dedicate
our new library to Mr. Smith
and the Urologic Research
Foundation in recognition of
their efforts on our behalf. We
are delighted to honor them in
this small way."
Smith, who has been presi
dent of the Urologic Research
Foundation since its creation,
was recently named chairman

of the board. Arnold Schwab is
the new president.
Smith 's association with
Washington University began
in 1920 when he was a student
in the business school. He
graduated in 1924 and received
his master's degree in econom
ics in 1926, the same year he
formed the Smith Insurance
Agency. He continues to be
involved in the insurance busi
ness with the firm Lawton
Byrne-Bruner. 
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ichard P Bunge, M.D.,
professor of anatomy
and neurobiology, will
conduct research for the next
seven years with more than
$900,000 in funding from a
Javits Neuroscience Inves
tigator Award.
Bunge is the ninth Washing
ton University faculty member
to receive a lavits Award since
the highly competitive awards
program began in October
1983. Award recipients are se
lected three times each year.
The U.S. Congress gives the
awards in honor of Sen. Jacob
K. Javits of New York, on rec
ommendation of the National
Advisory Neurological and
Communicative Disorders and
Stroke Council of the National
Institutes of Health . Javits was
a victim of amyotrophic lateral
sclerosis (ALS), more com
monly known as Lou Gehrig's
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disease. ALS is a degenerative
neuromuscular di sorder that
attacks the nerve cells that
control muscles.
The Javits Awards, given to
investigators who have submit
ted regular research grant
applications for competitive re
view, encourage research and
research training in commu
nicative and neurological disor
ders. The prestigious grants
provide a seven-year com
mitment of support to the
researchers who receive them.
Bunge is Beaumont-May In
stitute of Neurology SCDoiar in
Anatomy at the School of
Medicine. His grant will allow
detailed studies of the biology
of the Schwann cell , the pre
dominant helper-cell to the
nerve fibers of the peripheral
nervous system. The respon
sibilities of the Schwann cell
include production of myelin,
the insulating material of
peripheral nerve fibers, and
production of extracellular
matrix materials. The Schwann
cell is affected in several
human diseases, including
neurofibromatosis and Guil
lain-Barre syndrome, and is
believed to be a key cell in
fostering peripheral nerve
regeneration.
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R'geo Thorn'''. M.D .
assistant professor of
• otolaryngology, is one of
40 outstanding American pro
fessionals named to Group VII
of the WK. Kellogg Founda

tion's Kellogg National Fellow
ogy in Pasadena , uses recom
Bke . 'anwd P("W
binant DNA technology to
ship Program.
unravel the molecular details of
The Kellogg program pro
S(~hohll"
.h(~
how viruses reproduce. This
vides each fellow with a threetechnology opens up new
year, $30,000 grant that fund s
Biollwd i.·al
avenues for the design and
a study project outside the fel
Sd('Jl(·t·~
propagation of live vaccine
low's field of expertise. The
strains against RNA viruses,
foundation also will host edu
including yellow fever virus,
cational programs in the United
Rice explains. Also, he says, it
harles M. Rice, Ph .D.,
States and Latin America for
should allow researchers to ex
virologist and assistant
the fellows. Group Vll mem
professor of microbiol
plore the possible use of these
bers will address leadership de
viruses as transmitters for the
ogy and immunology, has been
velopment, focusing on such
chosen as one of 20 Pew Schol
cytoplasmic expression of
issues as the changing Ameri
ars in the Biomedical Sciences
foreign genes in animal cells.
can family, agricultural and
The goal of the Pew Memo
by the Pew Memorial Trust of
environmental resources for
Philadelphia .
rial Trust is to establish a
the future, and international
The 1986 Pew Scholars,
network of outstanding, in
interdependence.
novative researchers who are
Thomas is on staff at Barnes junior faculty members at 17
medical schools and research
Ii.kely to become future leaders
and Jewish hospitals, sponsor
institutes in the United States,
in the scientific community
ing institutions of the Washing
were selected in recognition of
The Pew Scholars Program is
ton University Medical Center.
their promi sing work in basic
administered at Yale University
Before joining the Washington
School of Medicine, and win
science or clinical research.
University faculty in 1983, he
Each of the scholars will re
ners are selected by a 13-mem
was clinical assistant professor
ber national committee.
cei ve a total of $200,000 over
of otolaryngological surgery at
Rice joined the Washington
the next four years to encour
the University of Missouri
University faculty earlier this
age resea rch for the advance
Medical Center.
year. He recei ved a Ph. D. in
He received the doctor of
ment of human health.
Rice's work, much of it done biochemistry from the Califor
medicine degree from the Uni
while he was a fellow at the
nia Institute of Technology in
versity of Missouri School of
1981. •
California Institute of Technol
Medicine in 1972. Thomas
trained in surgery at Yale Uni 
versity and in otolaryngology
at the University of Missouri
School of Medicine, and also
completed a fellowship in
facial plastic surgery at North
western University School of
Medicine.
He is currently vice presi
dent of the American Academy
of Fac ial Plastic and Recon
structive Surgery. He is also a
member of the American
Academy of OtolaryngologyHead and Neck Surgery, the
.,
American Board of Otolaryn- .,::l'"
gology, the American College :r:c
..c
of Surgeons, the American
.Q
Medica l Assoc iation's Com
miuee on the Young Physician,
Sindbis viruses, one type ofRNA virus that Rice is studying, bud
and the St. Louis Metropolitan
through the outer membrane ofa chick embryo fibroblnst cell.
Medica l Society
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CVS: Reborn Partner In
BY TONY DIMARTINO

fter deciding that there must be
more to life than an MBA and a
walletful of platinum credit cards,
Nina - well-established in her career at 37
- is pregnant for the first time. There's a
one-in-IOO chance that her child will be
born with a birth defect.
Liane lost her first child three years ago
to Tay-Sachs, a fatal brain disease. She's
now eagerly expecting her second child.
But there's a one-in-four chance that thi s
baby will also be born with Tay-Sachs.
Nina's age and Liane's genetic history
mark their pregnancies as high ri sk. Both
women are worried about their unborn chil
dren: are they developing normally, or do
they have genetic deformities that will cau se
severe birth defects, impaired quality of life,
or even death?
Currently, many high-risk mothers-to-be
wait anxiously until disorders in their un
born children can be detected with amnio
centesis. This prenatal diagnostic test
analyzes cells from the fluid surrounding
the fetu s. Amniocentesis can identify many
birth defects, but cannot be performed until
enough amniotic fluid has formed - at
least the 15th week. Results may take two
more weeks while the siphoned cells multi
ply into a sample large enough to study
But with an experimental screening
procedure called CVS -chorionic villu s
sampling - being tested at the School of
Medicine, results of cell analysis can be ob
tained as early as the ninth week of preg
nancy That 's at least six weeks earlier than
amniocentesis.
"The overwhelming advantage of
CVS over amnio is early diagnosis," says
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James P Crane, M. D., director of the
genetics division in Washington University's
obstetrics and gynecology department. "If
no birth defect is found, CVS provides
earlier reassurance to frightened parents
who might have considered ending the
pregnancy. "
[f a problem is diagnosed, Crane says,
CVS allows parents more time to prepare
for a handicapped child or, if the defect is
severe, to end the pregnancy much earlier.
"Early termination is safer for the mother
both physically and psychologically," ex
plains Crane, who also serves as director of
obstetrics and gynecology at Jewi sh Hospi
tal. "And first trimester detection of
abnormalities also paves the way for fetal
therapy, which may one day enable us to
treat and correct defects before birth ."
Fourteen other U.S. medical centers are
examining CVS' safety and reliability under
a Food and Drug Administration protocol.
[n March, Washington University made the
first national presentation of preliminary
CVS evaluation results. The study was
described in a poster session at a meeting
of the Society for Gynecological Investiga
tion in Toronto.
The researchers attempted to assess the
safety of CVS by comparing first trimester
miscarriage rates in 116 high-ri sk women
who underwent CVS to miscarriage rates in
75 high-risk women who did not have CVS.
There was one miscarriage among the
controls and two among the CVS group.
"One [CVS] miscarri age was due to a weak
cervix that dilated prematurely, totally unre
lated to the CVS procedure," says Crane.
'The other case is still under investigation."

Crane's group concluded that CVS did
not significantly increase ri sk of mis
carriage. "We've now done almost 200
CVS procedures," says Crane. " We've had
four more misca rriages since the meeting in
Toronto, but none of them appears to be
procedure-related. CVS is potentially as
safe as amnio."
The recent study did not compare amnio
and CVS head-to-head, but data available
worldwide shows that CVS seems safe.
Crane cautions that no definitive compari
sons can be made until many more CVS
procedures - perhaps 30,000 to 40,000 
are completed. Statistics are being collected
at the 15 U.S. centers and others abroad as
the CVS evaluation continues.
"So far, our diagnoses have been 99 per
cent accurate, and there's every indication
that CVS will eventually prove to be as reli
able as amniocentesis," says Heidi Beaver,
M.PH., a genetics associate. "We're just
waiting for more patients to be referred so
more diagnoses can be attempted. ,.
Amniocentesi s can identify about 200
abnormalities. CVS currently can detect
about 100 di sorders, but the procedure's
diagnostic range could increase.
Even so, CVS will never completely
replace amniocentesis because it can't de
tect neural tube defects - spina bifida and
other spinal column disorders, which are in
dicated by high levels of alpha-fetal protein
in the amniotic fluid. Also, some uteri are
positioned in such a way as to make it
difficult to obtain an adequate sample of
villus tissue.
CVS, performed at Jewish Hospital, takes
only 30 minutes, can be done without anes
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thesia and costs about $750, roughly the
same as amniocentesis. "Like amnio, CYS
is relatively painless," Beaver explains. "In
terms of discomfort , I'd compare amnio to a
blood test and CYS to a Pap smear."
The CYS procedure begins with an ultra
sound examination to determine the em
bryo's location and age. A thin, flexible
catheter is guided through the cervix to an
area between the uterine lining and the
chorion - a layer of tissue that surrounds
the embryo and eventually becomes the
placenta. A syringe is attached to the cathe
ter, and a sample of chorionic villi - tiny,
hairlike projections - is withdrawn.
About one one-thousandth of the chorion
is removed.
These cells can be examined almost
immediately. Not so with amniocentesis.
Collected through a hollow needle inserted
through the abdominal wall into the amnio
tic sac containing the fetus, fetal cells are so
scarce in the amniotic fluid that they must
multiply for at least two weeks in laboratory
cultures. The delay means that amniocen
tesis results often are not known until after
the 20th week of pregnancy, well into the
second trimester.
Genetics associate Beaver says CYS will
remain experimental until more centers pre
sent their studies and the FDA is sati sfied
that use of CYS catheters is safe.
At least four different catheters are being
tested, says Lillian Yin, Ph.D., director of
the FDA's Office of Device Evaluation.
"It is hard for us to estimate when CYS will
be available to the general public. Research
centers are sending their statistics on fetal
loss to the catheter companies, which in

turn will send them to us for review when
enough data has been compiled."
Both amniocentesis and CYS are con
sidered invasive procedures and pose a risk
of complications that might lead to mis
carriage. They are recommended only
when women will be 35 or older at the time
of delivery; when women have had a previ
ous child with a chromosome abnormality
such as Down syndrome; or when women
or their mates are carriers of a chromosome
translocation, a sex-linked disease such as
hemophilia or muscular dystrophy, or a
biochemical di sease such as Tay-Sachs.
CYS isn't new. In the late 1960s, about
the same time amniocentesis was being de
veloped, Scandinavian researchers showed
that chorionic villus tissue could be used for
prenatal diagnosis. But the miscarriage rate
was high at that time, and the procedure
was overshadowed by the early success of
amniocentesis.
It wasn't until the early 1980s that CYS
- improved by refined ultrasound tech
niques and availability of thin catheters that
made cervical dilation unnecessa ry 
began to catch on. The procedure was
championed by British and Italian research
ers and sponsored in the United States by
investigators at Jefferson Medical College in
Philadelphia, the University of California at
San Francisco, Michael Reese Hospital in
Chicago, and the Washington University
team in SI. Louis.
Within the next 10 to 15 years, experts
predict that first-trimester CYS will enable
doctors to diagnose potentially fatal birth
defects early enough to treat them before
birth. Many genetic disorders are caused by

Using a dissecting microscope, research
technician Nanette Fyan separates chori
onic villus ti.ssue from matemal tissue. The
villus tissue is cultured ovemight to gener
ate cells for chromosome analysis. Sau Wai
Cheung, Ph.D., standing, is the director of
the cytogenetics laboratory at Bames
Hospital, where the cells are prepared and
analyzed. Results of chorionic villus sam
pling can indicate the presence or absence
ofcertain birth defects as early as the ninth
week ofpregna.ncy.

a lack of some vital enzyme or substance.
In Tay-Sachs disease, for example, an
enzyme deficiency causes the abnormal ac
cumulation of fatty substances in brain
cells. By the second trimester, when amnio
centesis finally diagnoses Tay-Sachs, brain
damage has already occurred. " Early warn
ing that all is not well within the fetus may
eventually lead to treatment that will com
pensate for any dangerous excesses or
deficiencies," says Crane.
Experts predict, however, thatCYS will
raise as many questions as it answers and
pose hard ethical choices. Although the ulti
mate aim of early genetic screening is fetal
therapy, ability to discover problems cur
rently outstrips ability to solve them and
may continue to do so for many years. In
terpreting genetic messages adds fuel to the
abortion debate.
"We're not pro-abortion," says Crane.
"But many high-risk parents who've experi
enced the agony of watching their helpless
child suffer and die will tell you that they'd
rather not go through it again."
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Matters of
Technology and Technique
BY SUZANNE HAGAN

he matchbook-sized clear plastic device looked like a
miniature Pachinko machine. But Kim Walton wasn't
playing games. Instead, Walton - a technician in the
clinical chemistry lab at Barnes Hospital- was preparing to test
a few drops of serum using a state-of-the-art machine called
"Vision."
Walton uses this Abbott Laboratory device to analyze either
whole blood or serum. First, the sample is centrifuged through the
Pachinko-like maze of the sample holder; then, at the appropriate
location, a pre-measured reagent automatically mixes with the
centrifuged sample. Depending on which reagent is packaged into
the sample holder, Vision measures the concentration of blood
borne substances like cholesterol, glucose and uric acid. Soon,
technicians may use the personal-computer-sized device to assay
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In the clinical clU!mistry lab at Barnes Hospital, Jay McDonald (standing) studies test results generated by medical technologist Robert
Roggeman. Roggeman operates the Paralkl Analyzer, which performs 28 different tests and can malu! 7,800 analyses per day. This
machine will soon be replaced by an even more sophisticatedpiece ofequipment.
Left: The Vision System is a laboratory device that calculates and prints out the concentrations ofblood components, such as proteins or
electrolytes. Just two drops ofblood from afinger prick are sufficient for each analysis.
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blood concentrations of theo
with people doing their own
phylline and creatinine. And in
tests, and it was profitable. They
the future, Vision will be able 10
can't do this now; the hospital
measure concentrations of drugs
loses money, and they don't run
such as phenobarbital and
24 hours a day or abide by qual
phenytoin, as well as natural
ity control.
components like iron, calcium,
"My staff just ran an educa
albumin and bilirubin.
tional program for physicians
The Pachinko-like sample
who want to do their own labo
holder isn't the only innovation
ratory testing," he continues.
dirf'diul1 hy
nHll1ufadtlJ'('("s
touting'
,
in state-of-the-art equipment.
"Even though it was well
The Kodak Company has cre
attended, most of the physicians
the lah·~t in ··J(u~lp .. oor' h't'hnnlngy
ated a blood chemistry machine
walked out with the realization
that uses samples applied to
that they really didn't want to get
to
('(Illip
their
ol'liee
lahorufol"i("s: in
film disks. Technology is the
into it, once they were told what
watchword.
the
legislation in the state of
allothe)" hy
(114' Ii 110" l('([goe
that 1l1Hny"
"
,
Yet these days, it's not only
Pennsylvania requires for quality
samples that are bouncing
control."
lum).1
dUll('
around in search of equilibrium.
But Pennsylvania is one of
Physicians are pulled in one
few
states that have rigid quality
a hu!o!pjfal m" ('olllnl4'I'dal
direction by manufacturers tout
control standards mandated by
ing the latest in "foolproof'
law. A bigger factor, some ex
s"tt ing Otl (sid(' (he ph~'~id an "..;
technology to equip their office
perts say, is the changing reim
laboratories; in another by the
bursement pattern. Now the
knowledge that many laboratory
incentive is for private physi
tests should be done in a hospital
cians to perform tests in the
or commercial setting outside
office instead of sending them
the physician's private office;
out. And added to this are the
and in yet another by the chang
growing numbers of instruments
and the fact that there are few tests suitably
ing reimbursement policies for laboratory
that make many tests easy to perform.
easy to be done outside an accredited labo
Which way should the private practitioner
tests.
ratory. One exception, he says, is glucose
Some experts point to this as evidence
turn?
monitoring: "Blood glucose is measured by
that current trends are leading away from
M1SSINC LINK
diabetics who are highly motivated, they
centralized laboratory facilities and that
really want to take care of that blood
more tests will be done in physicians'
"One advantage of performing tests in
chemistry equipment. And they get infor
offices, at patients' bedsides, and at home.
the physician's office is that the person
mation within an acceptable range to be
Others point to the fact that many promi
performing the test knows the patient and
able to make their decisions. Is it really
could relate the test result back to the patient
nent teaching hospitals are only just begin
better than we can," says Patrick Murray,
ning a task that Barnes Hospital set about 17 highly accurate and precise? No. The
instrument they're using is not as good
years ago: dissolving individual labs and
Ph.D., associate professor of medicine and
as the ones in a clinical laboratory. But
moving them to one central facility, gaining
pathology at Washington University and
it's good enough for them to make sensible
efficiency as well as consistently strict
codirector of microbiology in laboratory
dec is ions. "
medicine. 'The same thing would apply to
quality control standards.
Jarett speaks with authority. Winner of
a patient who's performing a test at home
"I think that there has been a lot of talk
the Ernest Cotlove Award, given by the
about decentralization of laboratory facili
to monitor glucose or detect organisms
Academy of Clinical Laboratory Physicians
ties," admits Leonard Jarett, M.D. '62,
in urine. The patient might pick up a
and Scientists, he led the effort in 1969 to
Flexner Professor and chairman of the
slight change that we would consider
centralize Barnes Hospital's laboratory
Department of Pathology and Laboratory
insignificant.
facilities. Only now, he says, are other
Medicine at the University of Pennsylvania
"On the other hand, particularly for tests
major academic hospitals like Massachu
School of Medicine. "But the reality is not
performed with instruments, you may be
setts General and Brigham and Women's
as great as the talk."
misled by the simplicity of the testing pro
following suit. Why? "Profit. DRGs are not
Jarett says that this "trend" is mythical
cedure. You may not know when that test is
reimbursing like they used to," says Jarett.
because of two basic reasons: the rigid
accurate unless the appropriate quality con
"There used to be all these little fiefdoms,
quality control standards mandated by law,
trol tests are performed. With our volume
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ottests, wccan financially ju,tify running a
large numbcr of quality control tests. In a
physician's office, whcrc maybc only eight
or nine tests are pert(mned each day, it's
very difficult to justify spending the money
required for quality control."
"Training in the elements of quality
assurance and quality control is missing
in most independent setups," says Jack
Ladenson, Ph.D, professor of medicine and
pathology, "and this is thc key weakness if
untrained people are doing the work. It's
not that you can't learn how to pipette or put
a dipstick into a sample. But how do you
know that what you're doing is working
right? That requires some concepts of
statistics and quality assurance, which
I think is the real missing link in non
hospital-based labs."
Ladensen, who is president of the Ameri
can Association for Clinical Chemistry and
director of clinical chemistry in the division
or laboratory medicine, points out that in
a laboratory like Barnes ' , 10 to 30 percent
of samples tested aren't from patients:
in one way or another, they arc relatcd to
assuring quality.
"When you leave that out. evcntually
you're asking for problems, " he points out.
"We look at the tOlal picture of 'quality' 
is the test being done accur<ltely, precisely,
rapidly enough; is it the right test; should
there be additional tests - thcse are the key
components of the job we do."
So it's this no-win situation that has many
clinicians confused. Fortunately, a Physi
cian Outreach Program is aV<lil<lble through
Barnes Hospital. "This program is designed
I'or us to help physicians in their otllce do as
many tests as they can do well in their
office, with our help and quality control ,"
says Jay M. McDonald. M. 0., professor of
pathology and medicine and director of the
division of I<lboratory medicine. "And we
can hclp them determine what tests they
shouldn't do. We will do them very compe
titively. We can oller them other assistance
because we have all the hospital information
in one package and can transmit all kinds of
information from the hospital to help them
practice medicine, Our goal is not to do
their work. but to help them do the work
themselves and do il right."

Laboratory medicine at Washington
University is a clinical division that weds
pathology to medicine; practitioners
carry appointments in both departments.
Within the scope of laboratory medicine,
headed by Jay McDonald, are sections in
microbiology, clinical chemistry, blood
bank, hematologylhemostasis, and
immunology/HLA (human lymphocyte
antigens).
What gives rise to a new academic
specialty like laboratory medicine?
According to Leonard Jarett, who was
the nrst to head the new division at
Washington University, the normal pro
cess of instituting a new specialty
worked backwards: "Typically, a spe
cialty grows and becomes strong in the
community because of what's at the
medical school. Laboratory medicine
went the other way - it started out in
the community and then came back to
the medical school.
" At academic centers, internists. sur
geons and others often did individual
tests in their labs with no coordinated ef
fort. They were not usually interested in

residency training, teaching. quality con
trol or the consultative role that labora
tory physicians and scientists now play
Thus, at academic centers, laboratory
medicine is distinct from anatomic
pathology. Furthermore, laboratory
medicine reflects a more academic and
scholarly approach than that found in
traditional clinical pathology. "
Washington University was one of the
first academic medical centers to estab
lish a division of laboratory medicine.
Jarett, who now chairs the Department
of Pathology and Laboratory Medicine
at the University of Pennsylvania, says
that Washington University'S program in
laboratory medicine " is unequivocally
number one in the country."
He says that nationally, laboratory
medicine is in its " ... preteen period .
Future developments in the neld will de
pend on what happens in the medical
centers in Boston and at Johns Hopkins.
If those places develop strong academic
programs, we will jump immediately
from our preteen period to young
adulthood."

Sample holders in tlu: Vision System, which separates whole bwod into cells and
plasma and then m.i.x£s a correct amount ofplasma with reaKents.
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Jack Ladenson has developed an a5say for an enzyme that appears in serum after a myocardial infarction. He uses monoclonal antibodies
to measure the enzyme. Right: This cwse-up shows how the Paralwl Analyzer got its name.

FlNE-TUNINC IHACNOSIS
TypicaJly, private practitioners have
office laboratories that perform microscopy
and other tests. Many still send some of
their tests out to commercial and hospital
laboratories. Nevertheless. they want to do
what can be done in-house to increase
profits and speed turnaround time, yet
they're aware that quality control could be a
problem . So a Physician Outreach Service,
such as the one provided by Barnes Hospi
tal, is often just what the doctor ordered.
One of the private practitioners who's
found thi s service helpful is John William
Campbell, M.D. '77. FHS, now a specialist
in infectious di seases at the Grant Medical
Clinic in St. Loui s. Campbell, who was
chief resident in medicine, says that he
occasionally comes across patients whose
infections are difficult to diagnose. "Some
times the culturing techniques may be diffi
cult, or the blood tests fall into the gray
zone of interpretation," says Campbell.
Campbell says he plans to use the oui
reach service to help train the Grant Clinic
staff. which already has more training than
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is typical: One of the clinic's physicians'
assistants has training in medical technol
ogy. Says Campbell: "We do all the routine
things most laboratories do - blood
counts, sedimentation rates, urinalyses,
blood potassium levels. But most of our cul
turing is still sent out."
But there are limitations to what such a
consultancy can do, and the principal prob
lem is that it's really the patient who tells the
story, not the bodily fluids: "We're only
consultants," McDonald says. "We can't
palpate the abdomens, we can't look in the
eyes, and we can't take the histories."
Quality control isn't just an issue with
private physicians doing their own tests,
says McDonald. It's a major problem
in many hospitals. too: "In some hospitals,
there are untrained persons doing what
seem like the simplest tests, and they're
making errors. One of the things we're
setting a priority on nationally is to make
sure that the practice of laboratory testing
does not deteriorate because untrained
persons are performing tests."

To alleviate this, McDonald is participat
ing in a national task force that is looking at
the problem of quality control in glucose
monitoring. "How do you monitor glucose
and do it effectively?" he muses. "That's the
question we're trying to answer. Can it be
done well by nurses, or do you need to limit
the number of persons who do it? I don't
think it has to be done necessarily by regis
tered medical technologists; it just has
to be done by persons who've been trained
or retrained."
The task force on glucose monitoring,
organized by the American Diabetes Asso
ciation, wil.1result in a consensus report.
McDonald says that the answers obtained
here will help determine the way quality
control issues for other types of such tests
are handled: "You have to establish criteria
for analytical excellence."
Another group that establishes perfor
mance standards for a wide range of labora
tory tests is the NCCLS - National Com
mittee for Clinical Laboratory Standards 
a group in which Ladenson and Murray are
active.
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courage the patient from seeking
Ladenson and others have
necessary medical care."
worked with manufacturers like
Abbott and Ames to evaluate
ADVANTACES OF
chemical analyzers' perfor
ACADEME
mance. "In some cases," says
An academic entity like labo
Ladenson, "the machines per
ratory medicine, born of a union
form well. In others, the pre
between pathology and medicine,
cision is not what can be
is more than machine monitor
achieved in a laboratory like the
ing. In addition to the instruction
one at Barnes. In many cases, it
all students receive in laboratory
makes sense to do these mea
medicine, there is a vigorous re
surements in the physician's
search program. The division
office, while the patient waits to
currently has nearly $1.8 million
find out if the medication they're
in annual funding for 32 re
on needs adjustment. The major
search projects.
drugs that can be monitored
Says Ladenson: "We are de
with in-office devices are
veloping monoclonal antibodies
theophylline, digoxin and the
for measurement of isoenzymes,
anti-convulsant drugs. So these
which are the different forms of
are the tests most companies are
an enzyme. The reason we mon
trying to develop."
itor enzymes is usually to assess
Added to the push by manu
the extent of cell death. If we
facturers to sell physicians office
" ( f"('
have specificity in that measure
laboratory equipment is the
ment, then we can begin to
additional incentive to test in
('fli. !!" priOl'if. 011 lIa(icmalh
make much better predictions of
house because of the changing
the cell or organ involved."
reimbursement pattern. If a
•• II.ti(' 1I1'C ( H ,
p"'l('fi~·t'
Ladenson's research team is
clinician gets reimbursed by
working on one of the enzymes,
Medicare, for example, then the
alnr
IO('~ 1101
creatine kinase, that's a marker
laboratory doing the test must be
for cardiac cell death in myocar
the laboratory that bills Medi
'rio 'afc' ht' ',UI'" IllUra II d
dial infarction. They have devel
care. "This is different than
oped an assay specific for only
before," says Ladenson, "be
('I'fOnHi,,!!h I .
I· I' ( II ( r
the enzyme CK-MG, found pre
cause then, a physician who
dominantly in the heart. This
collected a sample could bill
assay is based on a unique
Medicare for the test yet arrange
monoclonal antibody they
for another laboratory to do it at
a lower charge. Now, there's an economic
They are instructed to test their urethral
developed that recognizes only the iso
incentive for clinicians to do these tests in
exudate. and within seconds the test results
enzyme CK-MB among the three iso
are available. If the test is positive, the pack
their own offices, since the cost of perform
enzymes of creatine kinase known to exist.
ing the test is generally less than what
age insert recommends that they see a phy
Besides being very precise diagnostic tools,
sician. But what the manufacturers neglect
these tests will help probe the mechanisms
Medicare will pay.
to say is that patients should also see a
The realm of home tests is also growing,
of these enzymes, thus adding to the fund of
physician if the test is negative because
basic science knowledge.
and more manufacturers are trying to cash
urethritis is not normal.
But this research is only one aspect of
in on a lucrative market. But Murray, who
"I think. the real burden is on the FDA to
what laboratory medicine is all about:
chairs the Clinical Microbiology Division of
determine which tests are really appropriate
the American Society for Microbiology, is
"We have to dispel the notion that the
laboratory is a black box," says Ladenson,
for home use. This particular test had al
skeptical of how useful to consumers many
"where you put a sample in, a number
ready been licensed for males, and the com
of these home tests will be: "I was at an
FDA meeting in Washington recently," he
comes out, and the whole process works
pany wanted to expand its use to females. In
says, "and saw a home diagnostic test for
fact, it shouldn't have ever been licensed.
through some sort of miracle. Without
knowledge of the process, you're just
It's not a precise indicator of the gonorrhea
gonorrhea. What was especially disturbing
micro-organism, and a negative test result
pushing a lot of numbers. And that's not
to me was that this is a test being marketed
information, it's just data."
in a symptomatic patient should not disfor persons who have signs of urethritis.
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Jtarming up to

Uhiquitin
BY

he gender of our offspring is not
something we primates leave
_ ungoverned; sex chromosomes
called "X" or "Y," nestled among the other
22 in sperm , determine whether we buy
pink or blue booties. Some turtles and
li zards, however, do things differently.
The sex of their offspring depends solely on
the temperature caressi ng their clutch of
leathery eggs. For map turtles, very low
(20 C) or high temperatures (31 C) induce
femaleness; mid-range temperatures pro
duce male offspring.
Heat, then, could be considered sexy be
cause of its strange and wonderful effec ts
on amphibians ' eggs. But the story doesn't
stop there. Across the realm of biology
from primitive, one-celled organi sms to
complex creatures like amphibians, bird s
and mammal.s including humans -the
application of a stressor such as heat brings
about profound changes within cell s.
Too much heat, of course, can be fatal to
cell s, congealing their proteins into a useless
glob. Cancer cells seem to be particularly
sensitive, which is why hyperthermia is part
of oncologists' armamentarium . But non
fatal amounts of heat applied to normal
cells stimul ate the production of what are
known as the heat shock proteins (HSPs).
We don't know whether HSPs cause sexual
differentiation in map turtles, ordaining th at
one clutch of eggs will be primarily fem ale
or male baby turtles. Exactly how the HSPs

T
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protect cells and enhance their survival
is unknown .
The effects of heat shock were first de
scribed about 25 years ago. Exposure to
heat prod uced marked changes in fruit fly
chromosomes.
During the next 15 years, the phenome
non was defined; new RNAs and new pro
teins, call ed HSPs, were identified. Yet
the heat-induced changes in fruit flies were
thought to be an interesting but isolated
anomaly. But in the late 1970s, research in
the fi eld of heat shock proteins took off.
When ex posed to heat, cells of most organ
isms, rrom bacteria to humans, displayed
these unu sual proteins.
Because their structure is identica l, or
nearly so, from one spec ies to another,
HSPs were believed to play an integral role
in all cells. Yet their actual function
remained a mystery.
No one is sure how many HSPs exist, but
their number is probably small. In chicken
cells, four major HSPs have been identified.
Three are known simply by their subunit
molecul ar weights: HSP-90, HSP-70 and
HSP-24. But the fourth , ubiquitin (so named
because of its ubiquitou s distribution from
spec ies to spec ies), wasn't even known to be
a heat shock protein until a few years ago.
Like so many important scientific dis
coveries, ubiquitin's identity as a heat shock
protein was serendipitous. Ursula Bond, a
predoctoral student in the laboratory of

Milton 1. Schlesinger, Ph .D. , was treating
cells with heat to see what new proteins
might be induced.
Rather than looking at the new proteins
themselves, she ex amined the messenger
RNA that carries instructions for their
manufacture.
"When I started to analyze the m-RNA
present in the cells after heat shock," says
Bond , "I found several RNA s that were in
duced. When I sequenced one of them, I
found it coded for ubiquitin. That was the
first time anybody had shown that ubiquitin
was a heat shock protein. "
Ubiquitin, a 76-amino acid protein, had
first been described in 1975. Becau se of its
widespread distribution among species,
and the fact that its amino ac id structure is
nearly identica l from species to species,
ubiquitin was thought to play an important
role in cells. But ju st how important is only
beginn ing to be understood.
"Ubiquitin is needed for all cells to go
through their cycle of cell division," says
Schlesinger, professor of microbiology and
inUlluno]ogy. "We think that ubiquitin's im
portance lies in its assoc iation with pro teins
known as histones, which are molecules
that interact with DNA in a highly orga
nized structure. It 's been known for many
years that about 15 percent of hi stones have
ubiquitin attached to them. This attachment
occurs only during a portion of the cell
growth cycle. When the cell gets ready to

-

Predoctoral student Ursala Bond discovered that ubiquitinformaLion is induced as temper
ature rises, mnking it a memher ofa still-mysterious famiLy ofproteins caLled heal slwck
proteins. Ubiquitin was so named due to its presence in a wide variety ofspecies.
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divide, these ubiquitinated histones release
their ubiquitin. Apparently, as soon as the
ubiquitin is released from the histone, the
chromatin condenses into a form that is
ready for cell division."
Besides its functions in the cell nucleus,
ubiquitin plays a second role. It serves as a
marker, tagging proteins that need to be
broken down. "The way the system works,"
remarks Schlesinger, "is that there's a set of
enzymes that recognize ubiquitin. In the
presence of ATp, these enzymes can activate
ubiquitin. The activated ubiquitin is then
attached to proteins destined for disposal.
A single protein can get many ubiquitin
molecules attached to it."
The remainder of this cellular protein
digesting scheme is unknown in detail, says
Schlesinger, but it too is dependent on ATP
"Most cellular protein-digesting activities
we're familiar with occur in compartments
- there are protein-digesting enzymes on

the membranes of the Golgi secretory sys
tem, and in Iysosomes and mitochondria.
But the ATP/ubiquitin system may be the
only protein-digesting system present in the
cytoplasmic part of cells. "
In addition to its function s in ceU division
and protein breakdown, ubiquitin has a
third role: It has been found on "homing
receptors." These are structures on the sur
faces of lymphocytes enabling them to
"home in on" and bind to tiny veins in the
lymph organ from which they originated 
their first "home."
"We really don't know whether the
ubiquitin found on these homing cell recep
tors is acting as a modulator of the receptor
structure," says Schlesinger. "It could be
affecting the receptor's function, as it does
for histones. Or if many molecules of
ubiquitin are present, it could be a mecha
nism for eliminating the receptor from the
cell surface."

Heat shock proteins like ubiquitin are
produced in response to several forms of
stress, including heat. In some way, the ap
plication of this stress triggers the so-called
"promoter" region that governs the activity
of genes coding for the heat shock proteins.
In fact, HSPs like ubiquitin have a unique
promoter region , the so-caJled "Pelham
box," named for its Cambridge discoverer,
Hugh Pelham.
"So there are two criteria that I consider
for any heat shock protein. " summarizes
Schlesinger. "It is inducible after heat or
some other stress is applied to cells. And its
production is governed by the Pelham box
promoter region."
"We've shown that the gene coding for
ubiquitin has all of the characteristics of a
heat shock gene," says Bond. "It has the
Pelham box. And you can see this gene
expressed when you give the cell several
forms of stress."
Bond has just sequenced the gene for
ubiquitin in chicken cells. This may be the
first complete sequence of the gene for
ubiquitin.
" It's a very simple gene, made up of mul
tiple copies of the protein-coding sequence
placed in tandem to each other," says Bond.
"And that makes it really unique. Also, it
has an intron - an intervening sequence of
base pairs, not part of the protein codeat one end. That was a surprise because
normally heat shock genes don 't contain
introns. "
The important roles played by HSPs gen
erally, and ubiquitin in particular, are only
just beginning to be understood. for the
ways that HSPs help cells tolerate stress
remain a mystery.
"Shortly after we began studying HSPs,"
says Schlesinger with a grin, "a colleague
warned that we might be ' hunting the
snark.' r think that 's unlikely. There's plenty
of evidence to indicate that we'JI soon know
what heat shock proteins do." •

Editor's Note: For further information, see
"Ubiquitin Moves to the Cell Surface,"
Science Magazine, 231, 21 February 1986,
796-7
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NTERFERONS
on TRIAL
BY LINDA SAGE

Lorraine Luebbert if Creve Coeur, Missouri,
has a new lease on life. In July 1985, her doctor
diagnosed kidney cancer and predicted death
within two nwnths. But seeking a second opin
ion, Lorraine had the kidney tumors removed
and entered an experimental interferon pro
gram at Washington University. She still has the
cancer, in the form

if metastatic growths on the

pancreas. But she is still alive to enjoy her
grandchildren.

Corrine Durand of Galesburg, Illinois,
doesn't have to look up the date of her son's
first interferon treatment - December 19,
1983, is engraved on her mind. In the previ
ous six months, Michael had undergone
laser surgery every two to three weeks for
recurrent growths on the larynx. Each oper
ation lasted over an hour and cost $3,500 to
$4,000. But with regular injections of in
terferon, the intervals between surgery
lengthened and then the growths dis
appeared. Michael is now a healthy 4-year
old and has needed neither surgery nor
interferon since June 1985.
In clinical trials, there may be only a few
such success stories, but each provides hope
during the long hours of research that fol
low. At Washington University, there is hope
among clinicians who are testing the anti
viral and antitumor properties of the in
terferons, a family of proteins that have just
become widely available.
In the division of pediatric otolaryngol
ogy, an interferon is on trial in the treatment
of recurrent respiratory papillomatosis, the
viral disease that afflicted Michael Durand.
In the division of urologic surgery, urol
ogists are testing two types of interferon
against renal cell adenocarcinoma, the
kidney cancer that has striken Lorraine
Luebbert. And pediatric oncologists will
see if an interferon can combat relapses of
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the most common childhood leukemia,
ac ute lymphoblastic leukemia.
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Pa pi Ilomas
Recurrent respiratory papillomatosis
(RRP) begins most often in children be
tween the ages of 12-24 months, though it
can occur at any age. Only 1,500 cases are
diagnosed in the United States each year,
but RRP can be devastating for those af
fected . A carbon dioxide laser can safely re
move most of the growth from the larynx,
windpipe or nasa l part of the pharynx , but
some infected tissue usually remains and
the tumor grows back . If it is on the vocal
cords, the first symptom is hoarseness. But
as it proliferates, like the top of a miniature
cauliflower, it can completely close off the
ai.rway - a tiny 5mm in diameter in a small
child. Children need an average of 13 oper
ations to clear them of the disease, but some
patients make hundreds of trips to the
operating room. And for parents, there is
the constant worry about the timing of the
surgery. 'The most traumatic thing is that
you don't know how far [the disease] has
gone," says Connie Durand. "You live on
pins and needles."
Inevitably, she and her hu sband once mis
judged the extent of the papilloma. One
night they found Michael bouncing in his
crib as he struggled for air. He had devel
oped stridor, the noisy respi.ration typical of
a blocked airway, and he needed immediate
surgery.
Other than interferon , there is little help
for patients like Michael. Radiation therapy
is ineffective and may convert the benign
growths into malignant tumors. Chemicals
applied directly to the vocal cords and
courses of antibiotics, steroids or chemo
therapeutic agents (s uch as 5-fluorouracil)
are also of little use.
In 1978, a Swedish physician who was
treating a woman with interferon for cervi
cal cancer noted that the plantar warts on
the woman's feet disappeared. Rea soning
that plantar warts are closely related to
laryngeal warts, he gave interferon to seven
children with respi.ratory papillomas. In
1981, he reported that most of the children
had improved dramatically.
Clinical tri als began at Washington Uni
versity in early 1982, when Harl an Muntz,

20

"
~

OJ
:>

,

•

ez::

'"

6 ,.

....l

Michael Durand with his mother, Corrine, at their home in Galesburg, Illinois.
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M.D. ' 77, assistant professor of otolaryngol
ogy and pediatrics, entered a study using in
terferon provided by Burroughs WelJcome.
In July 1985, assistant professor of otolaryn
gology and pediatrics Rodney Lusk, M.D. ,
joined the Washington University staff,
bringing experience of two other types of
interferon under investigation. Lusk had
previously participated in the study at the
University of Iowa.
The Burroughs Wellcome trial is one of
two carefully controlled studies to assess
the effectiveness of interferon against RRP
It involved 66 patients who previously re
qui.red laser surgery at least every two
months. Twelve of the patients were from
Washington University.
The patients were divided into two age
matched groups. After their last laser treat
ment , half the patients were randomized
into a six-month trial of interferon , and the
other half continued to have laser treat
ments. At the end of the six months, the two
groups were crossed over.
Only the data for the first six months
have been analyzed. Among the 33 patients
treated with interferon during that time
period, three responded completely and 15
had partial remissions, whereas none of the
patients in the control group improved.
Though heartened by these findings,
Lusk is not ecstatic: "Interferon is not going
to be a panacea for RRP," he says. " It is
effective in some children but not in all.
That may have something to do with the

type of virus since there are several sub
types, some much more severe than others."
At present , the Burroughs-WelJcome trial
is expanding to include RRP patients who
require surgery every three to nine months.
"Since interferon seems to be effective in a
certa in percentage of patients," says Muntz,
"less severely affected ones may also bene
fit. We'll be doing mostly adults becau se it's
a problem for them to take off from work
every few months to go to the hospital. And
between times, they have significant hoarse
nes s and symptoms of airway obstruction."

Kidney Cancer
Although RRP can be a major trauma, it
is rarely fatal. Not so with renal cell
adenocarci noma, which kills about 8,000
Americans each year, mostly men over 40.
The on ly treatment is early detection and
removal of the affected kidney. But diag
nosis is rarely made in time because the dis
ease is symptom-free in its early stages. If a
tumor grows large enough to cause prob
lems, metastases inevitably occur. Then,
there is no effective treatment because the
cancer is resistant to all forms of
chemotherapy.
Previou s studies showed that gamma in
terferon has some activity against renal cell
adenocarcinoma. For example, the protein
inhibited the proliferation of kidney cancer
cell s in tissue culture and slowed the growth
of human kidney tumors transplanted into
mice. And in preliminary clinical trials,
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about one-third of patients made some type
of response to interferon.
William Catalona, M.D., professor of
surgery (urology), Timothy Ratliff, Ph.D.,
research associate professor of surgery
(urology), and surgery resident M'liss
Hudson , M.D., began to test gamma inter
feron on 14 patients, including Lorraine
Luebbert, in August 1985. Their studies
were part of a Biogen trial with interferon
produced by recombinant DNA technology.
Of the 14 patients, six received only
progesterone, the approved but largely
ineffective treatment for renaLcell
adenocarcinoma. The other eight received
gamma interferon. CT scans at six-week in
tervals revealed that three of the test patients
had responded, though one later relapsed.
(Failure of the tumors to grow larger was
considered to be a response.)
"There are two potential mechanisms of
action," says Ratliff. "One is direct inhibi
tion of cell growth by interferon. The other
is interferon's ability to augment the im
mune response. It activates cells that attack
and kill tumor cells. It also enhances tumor
cells' expression of proteins that the im
mune cells recognize."
Now CataJona , Ratliff and Hudson are
taking part in a new multicenter study spon
sored by Schering-Plough. The patients will
receive gamma or alpha interferon alone or
together. The hope is that the latter will be
more effective. In tissue cultures of kidney
cancer cells, the two interferons halve the
rate of cell proliferation when combined at
concentrations where neither is effective
alone. The duo also decreases the growth of
human kidney tumors implanted into mice.
But Ratliff is tempering his optimism.
'These drugs are just experimental ," he
says. "We can't offer them to patients as
treatment. We are just trying to develop
new approaches for the use of interferons,
and we hope that this study will provide us
with better results than we have gotten in
the past."

Childhood Leukemia
Unlike the struggle against kidney
cancer, the fight against childhood leukemia
has been one of the success stories of the
last decade. Fifteen years ago, only 20 per
cent of children with acute lymphoblastic

l l 'hen alpha interferon was first de
scribed in Britain in 1957, it was dubbed
"imaginon" by scientists who doubted its
existence. But today, we have tangible
proof of its reality. Large quantities can
be prepared, either from a line of abnor
mal white cells or through recombinant
DNA technology. Copies of interferon
genes inserted into cultured cells such as
bacteria make the cells push out high
concentrations of the protein into the
medium.
The greater availability of the inter
ferons has led to numerous clinical trials
and, recently, to conunercial. availability.
[n March, Britain's Committee on Safety
in Medicines approved the sale of alpha
interferon tor the treatment of hairy cell
leukemia , an adult cancer. And in June,
the Food and Drug Administration
licensed Hoffman-LaRoche and Scher
ing-Plough to sell alpha interferon in the
United States for the same purpose.
The interferons promise to treat a
much wider range of conditions than
hairy cell leukemia, however. Recent
studies have shown that interferons can
protect cultured cells from the AIDS
virus, control genital warts and alleviate
the pain and inflammation of rheumatoid
arthritis. Moreover, nasal sprays of
interferon halt the spread of rhino
viruses, the most common of the
common cold viruses.
Neither the antiviral nor antitumor
activities are fully understood. But in
terferons are known to inhibit cell
growth and cell division, modulate dif
ferentiation and alter cell surfaces.
They also activate part of the immune
system. 

leukemia (ALL) were alive five years after
diagnosis. But thanks to new methods of
chemotherapy developed in the mid-1970s,
55 to 60 percent of the 2,000 new cases
diagnosed in the United States each year
survive for more than five years. And most
of those patients are cured because relapses
after four years are rare.

However, the Pediatric Oncology Group,
an organization of childhood cancer treat
ment centers, is rooting for the 40 percent
that succumb to ALL. At highest risk are
black chi Idren and males of all races who
are less than three years old and over six
years old, have high white cell counts at ini
tial diagnosis and rearranged or defective
chromosomes in the abnormal white cel Is.
If the cancer cells are derived from the pre
cursors ofT-cells, which form in the thymus
gland, the outlook is worse than for non-T
cell leukemia.
The pediatric oncologists will take part in
a clinical trial funded partly by the National
Cancer Institute. The study will determine
if interferon can help children who relapse
after chemotherapy and an initial remis
sion. "If you have a cancer that relapses in
spite of state-of-the-art therapy and high
cure rate, you are in trouble," says Vita
Land , M. D., associate professor of pediat
rics and one of the five WaShington Univer
sity pediatric oncologists involved in the
study. "Then it becomes ethical to introduce
a new therapy."
The patients will receive seven days of
alpha interferon treatment followed by stan
dard chemotherapy. The latter usually
brings a child into a second, temporary re
mission , and interferon therapy will con
tinue periodically during that time.
Interferon is active against ALL cells in
culture and in animals. Also, it has helped
adults with ALL or a closely related cancer
of the lymph glands. "However, children
aren't necessarily little adults," cautions
Land. "Just because interferon seems to
have activity in adult leukemia doesn't mean
that it will work in kids."
Clinical trials with experimental drugs
such as interferon are carefully evaluated by
both federal and university personnel. The
ALL protocol was approved by the Food
and Drug Administration and the National
Cancer Institute in March 1986 and by the
Human Studies Committee of Washington
University School of Medicine's Institu
tional Review Board in May. If the therapy
proves very effective, the next stage would
be a controlled trial with newly diagnosed
patients. So as with the RRP and kidney
cancer trials, the verdict will not be in for a
while. But there is hope among the jury. 
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RHODES
Hits The
ROAD
B Y CAN D ACE 0' CON NOR

s a promising biology student at
St. Olaf College, Sarah Bronson
hadn't quite decided whether she'd go
on to graduate school. Then she spent last
summer as one of 15 undergraduate re
search interns in Washington University's
Division of Biology and Biomedical Sci
ences, and her summer experience resolved
all her doubts. This fall, she's a brand-new
predoctoral student working in molecular
immunology. Her early reaction to the pro
gram? "It's even better than last summer,"
she says happily.
This kind of success story is a tribute to
Washington University's recruitment pro
gram, one of the most active among univer
sities. With tools such as the summer

A
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research internship, the aim is to attract top
notch students to Ph.D. and M.D.lPh.D.
programs in the graduate division. And this
effort has been extremely effective, yielding
a bumper crop of fine students like Sarah
Bronson. In recent years, for example, ap
plications from small liberal arts schools
- a special recruiting target - have in
creased five-fold.
"The quality of our applicant pool is
better than ever," says Carl Rhodes, Ph.D.,
research associate professor of biological

chemistry, associate director of the division
and director of graduate training. "When
we offer admission to top students, they
may instead choose Princeton, MIT or
Stanford. The competition for the best stu
dents is now greater, so the percentage
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Kathy Buchanan, a promising under
graduo.Je at Colorado College, Colorado
Springs, had the chance to test herselfin
research and "a graduo.Je study atmo
sphere" during her summer work at
Washington University. EXi:ellent small
schools such as Colorado College have been
targeted by the School ofMedicine as a
source ofprospective graduate students.
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we are able to enroll may not be as high.
But in the end we will have better students."
Reaching these students requires year
round work by Rhodes, who heads the re
cruitment effort, and his four-member staff.
In late summer, they mail more than
1,000 posters and brochures to every major
biology and chemistry department in the
country. Within weeks, Rhodes is airborne,
visiting some 25 campuses. Each year, he
adds new schools to his itinerary; last fall,
he made his first stops at Bates, Bowdoin,
Colby and Trinity (Texas). His goal is to
meet students and cement ties with sym
pathetic advisers, usually faculty members
whose active research programs entice stu
dents interested in graduate work.
While most science faculty at these
schools already know Washington Univer
sity, the students may not. "The joke I use
in speaking with them is that we're neither
six blocks from the White House nor on
Puget Sound," he says. 'The fact is,
though, that a lot of them don't know where
we are."
They may also have misconceptions
about graduate work. During his visits,
Rhodes often gives a "neutral" seminar, ex
plaining what students should look for in a
Ph.D. program and what admissions com
mittees will expect: "All sorts of things
come up. Students may not realize how well
qualified they are for graduate school.
Sometimes they don't even know they can
receive tuition and a stipend for their gradu
ate work. They think they'll have to borrow
the money."
At some schools, Rhodes also finds that
he's a new phenomenon. Though Princeton
is beginning to initiate a similar program,
other graduate institutions just don't do
Washington University's kind of personal
recruiting at the graduate level. A genial
and energetic man with a strong concern for
students, Rhodes has clearly provided some
of the impetus for this major recruiting
effort. When he arrived three years ago
after administrative posts at NIH and Stan
ford, the time seemed right: A rush of new
faculty and a one-to-one faculty/student
ratio were extremely attractive. After a
lapse during the Nixon administration,
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federal funding - primarily NIH training
agents - was available.
Since then, Rhodes has gained solid re
spect for his work, says Ted R. Johnson,
Ph.D., head of the Biology Department at
St. Olaf College: "Frankly, we get lots of re
quests by recruiters to give seminars, but
we honor very few of them. Carl Rhodes'
seminar, though, is extremely helpful to the
students. "
Even though he travels to big schools like
the University of Washington and Cornell,
Rhodes says that recruiting from them can
be difficult. There may be more than 1,000
undergraduates in the biological sciences at
one of the larger schools; advising is often
done on an alphabetical basis. He prefers to
concentrate on small liberal arts colleges.
Traditionally, they have a high percentage of
science majors who go on to do weI I in re
search. They also have an excellent track
record here: since 1978, some 25 percent of
division graduates have come from small
colleges.
These schools also supply the under
graduates for Washington University's
summer internship. Since 1982, when three
biology students came from Kalamazoo
College, the program has grown to a maxi
mum of 15 students per summer, drawn

from various colleges. These students, usu
ally incoming seniors highly recommended
by their own science professors, spend three
months here working on a research project.
'The idea is to give them a view of grad
uate work at a large institution," says
Rhodes. "But you might ask what's in it for
us? We hope that when they go back, they
will tell other students about the experience
they had here," Rhodes says.
One of last summer's group is Michael
Kyzer, a chemistry major from Hendrix
College in Arkansas. After working in the
laboratory of Maynard V Olson, Ph.D.,
associate professor in the Department of
Genetics, Kyzer is enthusiastic about his ex
perience. "It's wonderful. I'm surprised
they've allowed me to do so much indepen
dently." He plans to tell other Hendrix stu
dents about his summer internship. Will he
apply here for graduate study? "Definitely,"
he says.
In recruiting students to summer and
graduate programs, Rhodes says, the repu
tations of the divisions' 230 faculty mem
bers play an important part. "If we didn't
have a good faculty, it wouldn't matter what
I did. We wouldn't attract anyone," he says.
The innovative Washington University
graduate program is also a strong selling
point. In 1973, the Division of Biology and
Biomedical Sciences was organized as a
consortium of seven medical school depart
ments, plus the Department of Biology on
Hilltop campus. Rather than traditional
concentrations along departmental lines, the
new division offers five interdisciplinary
programs: Molecular Biology and Bio
chemistry, Cell and Integrative Biology,
Plant Biology, Population Biology, and
Neural Sciences.
The 220 graduate students in the divi
sion, which is now directed by Daniel
Hartl, professor and head of genetics, still
enjoy a sense of freedom unmatched at
most institutions. During their first year,
they can readily switch from one program
to another. They can also rotate among two
or three labs to see where personalities and
research interests best mesh.
This openness is a boon to recruiting,
says Johnson of St. Olaf College, who last
year sent three of his four top students to
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Carl Rhodes, associnie director of biology and biomedical sciences, discusses research progress with an uruiergradua1e research intern, Jeff
Zachs. In a program conceived by Rhodes, promising undergraduates receive research experience lUldfamiliarity with Washington Univer
sity through summer internships.
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the division. "In many graduate schools,
students come to work with a specific ad
viser or in a designated area. At Washington
University, they can shift around. For our
students, whose interests L,ay not be
focused yet , this is a great advantage."
Julie Hatch , a Sl. Olaf graduate and
fourth-year student, used that freedom to
pin down her own research interests. She
stayed in her third rotation, working in the
laboratory of Susan E. Cullen, Ph.D., asso
ciate professor of genetics and microbiology
and immunology. Now, she enjoys the spirit

of cooperation that exists between pro
grams. "There's a lot of interaction between
departments. J'm interested in cell biology,
but J hear what's going on in pathology and
other areas," Hatch says.
The Washington University graduate
division is not for everyone. One summer
student discovered his true vocation during
his stay - and is now in a Lutheran semi
nary. And those who wish to apply will find
that the school is highly selective. Last year,
of 450 applicants, only 85 were offered ad
mission and 44 finally came.

But Rhodes hopes that , through the vari
ous aspects of his recruiting program, he
can reach those students who would benefit
by a Washington University graduate educa
tion. Mike Kyzer is convinced. "I plan to go
back to Hendrix with many, many positive
things to say. The Washington University
faculty is supportive and knowledgeable in
many fields. Students can pursue their own
interests and not just become satellites
of an investigator. For a graduate student,
it's a very attractive place to get an
education. "
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The Unnatural History ofthe 1110vement
Against Animal Experimentation

......
eventy years ago, infectious diseases
stalked the land with far greater cer
tainty of death than AIDS does now.
Everyone could experience Mimi's hopeless
agony as she slowly expired from con
sumption (tuberculosis) in Puccini's "La
Boheme." Surgical procedures that we now
take for granted were still being developed
and perfected; little could be done to stem
the usually fatal course of post-operative
infection.
Progress in medical care is a testament to
human imagination, the dedication of
health care professionals, and society's abil
ity to solve important problems. Studies
using animals as research subjects have
sharpened considerably the effectiveness of
health care and broadened the scope of its
services. Experiments on animals have led
to corneal transplants (rabbits; Am. J
Ophthal. 34 (1951): 142), immunization
against polio (chimpanzees; Am. J Hyg. 5 I
(1950): 85), removing blood clots (dogs;
Circulation 72 (1985): 18), treatment of dia
betes (dogs: J Lab & Clin. Med. 7 (1922):
251), and the spectacular rise of cardiovas
cular surgery (dogs; lAMA 128 (1945): 189).
Better diagnosis, treatment and prevention
have immeasurably improved the lives of
humans and our animal brethren.
Despite many spectacular advances, the
future of scientific medicine is threatened in
the name of "animal rights." Laboratories at
the University of Pennsylvania Medical
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School were raided on the 1984 Memorial
Day weekend. Sixty hours of videotapes
documenting experiments for a head injury
project were stolen by ALF (Animal Liber
ation Front). Soon afterward, PETA (People
for the Ethical Treatment of Animals) dis
tributed a slick video, "Unnecessary Fuss,"
extracted from the stolen tapes. The PETA
video, narrated by Ingrid Newkirk, is not
pretty. It would turn the stomach of anyone
not familiar with the tragedy of head
injury and its devastating effects. Yet
these stomach-churning experiments are
one of the few hopes the victims and their
families have.
Last summer, in response to intense
political pressure, then-Secretary of Health
and Human Services Margaret Heckler
suspended federal funding for the Penn re
search. Subsequent raids on laboratories
throughout the country have often been
followed by surprise inspections of animal
facilities and research laboratories by the
National Institutes of Health (NIH). Early
this year, all federal funds awarded to
Columbia University were withheld for six
months after such an inspection, no doubt
further providing positive reinforcement for
animal rights activists.
Now, the NIH itself is under attack.
PETA accuses the NIH of mishandling the
care of a group of monkeys seized several
years ago from a Silver Springs, Md.,
laboratory. The activists have enlisted

Congressional support in pressuring the
NIH to tum the animals' care over to a pri
vate sanctuary.
The response of individuals in the
biomedical community to these challenges
has been slow, weak and poorly organized.
Is this because we believe that the problem
will go away? If history tells us anything, it
is that this bel ief is patently absurd.
The animal rights movement is not new;
it sprang up in eighteenth-century England
and America as a radical offshoot from
humane societies. Then, as today, humane
societies provided essential services, such as
caring for and disposing of stray dogs and
cats. Antivivisectionists, as the radicals
were then called, attempted to abolish
animal experimentation and, failing that,
to regulate it into oblivion.
Antivivisectionists in the 1800s assumed
that all animal experimentation was painful
and cruel. They also accused sciyntists of
being immoral atheists and questioned the
validity of scientific progress. Boldly politi
cal tacticians, anti vivisectionists had "cells"
located in cities. These vigorous, well
financed, political organizations recruited
supporters, published pamphlets and won
over influential clergy and politicians. Their
efforts were rewarded by the Cruelty to
Animals Act of 1876, which is still the basis
for regulation of animal experimentation in
England.
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As early as 1867, attempts at similar
legislation began in the United States. The
leaders of American medicine organized
strong, successful opposition to the Con
gressional bills of 1896 and 1900. Their case
was bolstered by the demonstrated value of
animal research in surgical antisepsis (pub
lished by Lister in 1867, based on his direct
observations on inflammation in experi
mental animals), antitoxin treatment for
diphtheria (introduced by Behring in 1893,
after he and Kitsato demonstrated that
serum from animals exposed to diphtheria
toxin protected other animals from the
disease), and other discoveries that im
proved the health of humans and animals.
Re-emerging in cyclical fashion throughout
this century, the animal rights movement
has gained renewed strength.
Historians have examined the movement
with a dispassionate eye. They note that
antivivisection agitation preceded animal
experimentation in English and American
medical schools. In the historians' view,
concern over animal welfare masked
ulterior motives. Under the powerful rally
ing cry of antivivisection seethed other con
cerns: nationalism , political expression for
unenfranchised women, and difficult-to
articulate problems like the displacement ,
squalor and suffering brought on by the
industrial revolution.
Since the concept of animal rights is not
new, nor is the sensitivity to animal suffer
ing, it is not clear whether ulterior motives
underlie the present resurgence opposing
animal experimentation and harvesting of
animals for food, clothing and sport.
On the Today show of July 18, 1985,
PETA's Newkirk commented: "If it [animal
experimentation] were such a valuable way
[to gain knowledge] we should have eternal
life by now." This refrain is strikingly
similar to one made by antivivisectionist
Matthew Woods in 1900: Given the number
of experiments on the brain done up to
that time, he said, the insane asylums of
Washington, DC should be empty.
Indeed, most of the current strategies are
strikingly similar to those of antivivisec
tionists : publicize, misrepresent, find sup
portive "medical friends" and atlempt to
limit funds for biomedical research. Even

Tho/1UIS A. Woolsey, M.D.
more ominous are the breaking into, the
theft from and the destruction of laborato
ries, and the direct threats on the lives
of working scientists.
Those who advocate the cessation of
animal experimentation have the right to
express themselves. But how humane is it to
deprive of hope victims of senile dementia ,
stroke and cancer - problems that affect a
growing proportion of our population with
almost unbearable immediacy? Answers
can only come after years of intensive study
on experimental animals. It is clearly in our
interest to adopt alternatives to animal
experimentation - models - when these
models more quickly lead to the right
answers. But at present, there are no
suitable experimental models that can be
substituted for animal experimentation in
research on senile dementia, stroke
and cancer.
Scientists are not inhumane, immoral
monsters who delight in torturing helpless

creatures. On the contrary, we have that
exceptionally deep respect for all of life,
including human, that can only come from
years of intensive study. As health profes
sionals, we feel a deep sense of responsi
bility to those we serve. I believe that part of
that responsibility is making sure, to para
phrase Dr. Mary Putnam Jacobi in 1900,
that "knowledge is not dominated by igno
ranee." The record is clear; careful , well
thought-out experiments on animals have
vastly improved veterinary practice and
medical care. Such work can make, and has
made, the difference for their well-being
and ours .

Thomas A. Woolsey, M.D.
Professor, Anatomy and Neurobiology and
Cell Biology and Physiology
George H. and Elhel R. Bishop Scholar
in Neuroscience in Neurology and
Neurological Surgery
Professor ofNeurology and Neurological
Surgery
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aulo. Hagemann, M.D.
'34, clinical professor
emeritus of the Wash
ington University School of
Medicine, has received the
prestigious William Greenleaf
Eliot Society Award.
William Van Cleve, presi
dent of the Eliot Society, pre
sented Hagemann with a silver
and marble replica of the sculp
ture 'The Search," designed
by Heikki Seppa, professor of
art at the university.
Hagemann, an active parti
cipant in alumni affairs, is a
life member of the Eliot Soci
ety. He has served on the
university's Alumni Board of
Governors and now is vice
chairman in charge of the
Planned Giving Committee.
Hagemann was a key person in
the development of the plrinned
giving program and has estab
lished an endowed scholarship
in the School of Medicine. His
leadership in the Medical
Center Alumni Association
began early when he served as
chairman of the flfth reunion of
his class of 1934.
Marvin Levin, M.D. '51,
professor of clinical medicine,
who served both his residency
and internship under Hage
mann, calls him an "astute and
caring" physician. "He had a
good relationship with his pa
tients," recalls Levin. "He set a
good example for his students,
interns and residents. "
The Eliot Society is an or
ganization of university alumni
and friends. The society is
named after the university's
founder, the Rev. William
Greenleaf Eliot. Each year the
society honors an individual
who has given outstanding ser
vice to the university, chosen
by an anonymous committee of
the society's members. Last
year's award recipient was
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Tom F. Wha)'ne, M.D. '31,
is professor emeritus at the
University of Kentucky College
of Medicine. He is writing a
history of preventive medicine
in World War II and directing a
program on the Oral History of
Medicine in Lexington and
Fayette County, KY

..

Robert A. Wise, M.D. '36,
is professor of public health
and occupational medicine at
the University of Texas School
of Public Health, and clinical
professor of internal medicine
at Baylor College.

O. Elliott Ursin, M.D. '36,

PaulO. Hagemann, M.D.
Zane E. Barnes, chairman and
chief executive officer of
Southwestern Bell Corp.
Hagemann is a graduate of
the Washington University Col
lege of Arts and Sciences and
received his medical degree
from the university's School of
Medicine. After his internship
at New York Hospital, he be
came an assistant resident at
New Haven Hospital in Con
necticut, where he was a
Sterling Fellow in the research
department. He returned to the
Washington University Medical
Center in 1937 to work as a
resident at Barnes Hospital. He
later joined the faculty of the
School of Medicine as an in
structor in medicine.
By 1944 he was serving as
assistant professor of cI in ical
medicine and director of the
Barnes Hospital laboratories
when his service with the U.S.

Army took him to Los Alamos
with the Manhattan Project.
Hagemann was part of the
team that monitored the first
atomic explosion in New
Mexico. He later traveled to
Hiroshima, Japan, to evaluate
residual radiation in that area.
Hagemann returned to his
private practice and teaching
responsibilities at the School of
Medicine in 1946. He was later
appointed chief of medicine at
St. Luke's Hospital and estab
lished the training program
there that serves as Washington
University's Postdoctoral Pri
mary Care Training Program
in Internal Medicine.
He has served as a Diplo
mate of the American Board of
Internal Medicine, and was
given the Distinguished
Alumni Award at Founders
Day in 1983 and the School of
Medicine's Alumni/Faculty
Award in 1984.

served in the U.S. Army Medi
cal Corps for 32 years, and re
ceived a distinguished service
medal. After retirement, he
attended the University of Oslo
for one semester, and then was
medical director of a nursing
home in San Antonio.

Lawrence W. O'Neal,
M.D. '46, is chairman of the
Department of Surgery at
SI. John's Mercy Medical
Center in St. Louis and pro
fessor of clinical surgery at
St. Louis University.

Ann DeHuff Peters, M.D.
'46, is clinical professor of
pediatrics at the School of
Medicine, University of
California at San Diego. She
was president of the American
Orthopsychiatric Association
in 1981.

Harry S. Jonas, M.D. '52,
FHS, dean of the University of
Missouri-Kansas City School
of Medicine, has been named
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president of The American
College of Obstetricians and
Gynecologists (ACOG).
As a private practitioner in
Independence, MO, from 1956
until 1975, Jonas delivered
more than 7,000 babies. He became full-time professor of
obstetrics and gynecology at
the University of MissouriKansas City School of Medicine, and chairman of the OBI
GYN department at Truman
Medical Center, the University's teaching hospital. Since
1978 he has been dean of the
medical school.
Jonas was instrumental in
the successful passage of a
public bond issue which built
the teaching hospital for the
medical school. Truman Medical Center is a public hospital
serving a large number of indigent patients, including many
who are high-risk obstetrical
patients.
He has held many positions
with state, regional, and national OB/GYN societies. For
the past 25 years he has been
an active member of ACOG.
He chaired the College's Health
Care Commission , which
studies and makes recommendations on those issues facing
practitioners of obstetrics
and gynecology. He chaired
ACOG's Missouri Section and
the South Central District and
was a member of the national
Committee on Professional
Liability. For the past year, he
served on ACOG's executive
board as the president-elect.
He is chairman of the
Obstetrics Section of the
Southern Medical Association,
a board member of the Truman
Medical Center, past member
of the Governor's Task Force
on Rape Prevention, and past
president of the Kansas City
Gynecological Society.

He has served four terms as
a member of the regional
screening panel of the President's Commission of White
House Fellowships. A member
of several professional soc ieties, he has authored a number
of scientific journal articles and
textbook contributions.
Jonas completed his OBI
GYN residency at BarnesSt. Louis Maternity and
St. Lukes hospitals.
Jean A. Chapman, M.D.
'53, FHS, of Cape Girardeau,
MO, a specialist in internal
medicine and allergy, has been
elected to Fellowship in the
American College of Physicians (ACP).
Chapman received a B.S.
degree frol11 Southeast Missouri State College in Cape
Girardeau in 1949, and an addi
tional B.S. in medicine with an
M.A . in Anatomy from the
University of Missouri in 1951.
After completing his M.D. , he
went on to become a medical
resident at St. Louis City Hospital on the Washington University Service.
Daniel M. Divack, M.D.
'56, is an obstetrician and
gynecologist in private practice
with appointments at Long
Island Jewish Hospital and the
State University of New York at
Stony Brook .
Havner H. Parish, M.D.
'56, retired after 25 years of
private practice in urology. He
lives in Pittsboro, NC, is a pilot
and plays the bassoon .
Morris Reichlin, M.D.
'59, received the 1986 Provost's
Research Award from the University of Oklahoma Health
Sciences Center. A professor of
medicine in the au College of
Medicine, Reichlin was one of
two recipients of the annual
award, which recognizes per-

sonal achievement in original
research. His interests center
on the immunological.aspects
of arthritis and the improvement of diagnostic procedures
for certain immunological diseases, particularly systemic
lupus erythematosus and polymyositis, an inflammation of
the muscles.
Raymond G. Schultze,
M.D. '59, became administrative vice-chancellor and director of UCLA Medical Center

Raymond G. Schultze, M.D.
on September I. He has been
the center's director since 1980.
The combined appointment
links responsibility for management of the 71 I-bed center
with administrative functions
for the campus.
Schultze holds the B.A. and
M.D. from Washington University. He served his internship
and residency at UCLA.
In 1965, he returned to
Washington University as a
United States Public Health
Service Postdoctoral Fellow,
and was also appointed to the
faculty as instructor and then
assistant professor of medicine.
Returning to UCLA in 1969,
he became assistant professor

of medicine. He was promoted
to associate professor in 1973
and to professor in 1978.
Within the Department of
Medicine at UCLA, Schultze
has served as chief of the divi
sion of nephrology, executive
vice chairman and acting chairman. He was associate dean for
administration in UCLA
School of Medicine from 1979
to 1986.
William I. Goettman,
M.D. '58, was inducted into
Wittenberg University's Ath
letic Hall of Honor.
Goettman was co-captain,
Most Valuable Player, All-Ohio
Athletic Conference and AIIOhio for the 1952 and 1953 bas
ketball seasons at Wittenberg.
He set what was then a school
single-game scoring record
with 38 points against Ohio
Wesleyan. Goettman was also a
standout tennis player, holding
the number one spot in singles
and serving as captain of the
doubles team.
A Danforth Scholar,
Goettman served 12 years as
team physician for the Tigers'
athletic squads. He was a chair
of the Tiger Fund during "The
Campaign for Wittenberg" that
raised over $20 million.

'60.
John T. Crosson, M.D.

'61, is associate professor in
the Department of Laboratory
Medicine and Pathology at the
University of Minnesota. His
hobbies include tennis, music
and running, and he has
completed four marathons.
Phillip E. King, M.D. '61,
is associate clinical professor in
radiology at West Virginia
University Medical School. He
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also has a private practice
and appointments at several
hospitals.

and nuclear medicine, is in solo
practice in Henderson, NC. He
also heads a recruitment pro
gram that has tripled the
number of physicians in his
rural area.

hospital in the United States.
Approximately 70,000 pediat
ric imaging examinations (con
ventional diagnostic x-ray,
ultrasonography, computed to
mography, nuclear medicine,
digital radiography, angiogra
phy, interventional procedures,
magnetic resonance ,imaging)
are performed annually.
Kirks, chief of the section of
pediatric imaging in the De
partment of Radiology, has
been at Duke University Medi
cal Center since 1978. He is
secretary of The Society for
Pediatric Radiology and chairs
the pediatric radiology pro
gram for the Radiological Soci
ety of North America. As
member of the Executive Com
mittee of the Association of
University Radiologists, Kirks
is editor of Pedifuru: Radiolog):
associate editor of Radiology,
reviewer for the American lour
nalo/Roentgenolog): and ex
aminer for the American Board
of Radiology.
Dr. Kirks has published over
250 abstracts, scientific papers,
review articles, and textbook
chapters during his .14 years in
academic pediatric radiology.
His textbook, Practical Pediat

Donald R. Kirks, M.D.
'68, currently professor of ra

ric fmLlging : DingIWstic Radiol
ogy o/In/ants and Children,

diology and pediatrics at Duke
University Medical Center, has
been appointed chairman of
the Department of Radiology
at Children's Hospital Medical
Center, Cincinnati, OH, and
professor of radiology and
pediatrics, University of Cin
cinnati College of Medicine,
effective September 1, 1986.
The 330-bed pediatric institu
tion is the largest children's

was published by Little, Brown
and Company in 1984. He re
ceived the John Caffey Award
of The Society tor Pediatric
Radiology in 1979 and the
William E Barry, Jr. Resident
Teaching Award of the Depart
ment of Radiology at Duke
University Medical Center
in 1985.
Kirks, a native of Ft. Worth,
TX, received his B.A. from
Rice University in 1964 and

Carl Mitchell, M.D. '61, is
in private practice in Nashville,
TN, and is clinical assistant
professor of medicine at
Vanderbilt University and the
University of Tennessee.
Gordon W. Philpott, M.D.
'61, is professor of surgery at
Washington University School
of Medicine. His hobbies are
fishing, photography and vege
table gardening.

Shigemi Sugiki, M.D. '61,
is associate clinical professor
of ophthalmology at the Uni
versity of Hawaii School of
Medicine. He also has appoint
ments at Kuakini, Straub and
St. Francis hospitals and the
Queen's Medical Center. This
year he became president of
the Hawaii Ophthalmological
Society. He is also an instructor
in aikido.

H. Michael Jones, M.D.
'66, a specialist in pathology
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M.D. from Washington Univer
sity School of Medicine in
1968. After a medicine intern
ship at Parkland Memorial
Hospital in Dallas, Kirks com
pleted a residency in diagnostic
radiology at the University of
California, San Francisco
Medical Center and a fellow
ship in pediatric imaging at
The Hospital for Sick Children
in Toronto. He was a staff pedi
atric radiologist at Children's
Hospital Medical Center,
Oakland, CA, and Children's
Medical Center, Dallas. TX ,
before joining the Department
of Radiology at Duke
University.

Roger Warnke, M.D. '71,
is associate professor of pathol
ogy at Stanford University
School of Medicine.

Darwin C. Jackson, M.D.
'76, an obstetrician and gyne
cologist, has appointments at
Washington University School
of Medicine and Barnes,
Jewish and Deaconess hospi
tals in St. Louis. His awards
include Teacher of the Year,
1983-84 from the Department
of Obstetrics and Gynecology.
and Outstanding Young Men of
America, 1985.

Association tor the Advance
ment of Science held recently
in Philadelphia.

Leo A. Whiteside, M.D.,
FHS, was named a member of
the Board of Directors of the
American Academy of Ortho
pedic Surgeons at the associa
tion's recent annual meeting in
New Orleans.
Whiteside is chief of ortho
pedic surgery and director of
the biomechanical lab at DePaul
Health Center, Bridgeton, Mo.
He is research assistant pro
fessor of orthopedic surgery at
Washington University.
Born in Pampa, Texas,
Whiteside has a B.S. from the
University of Oklahoma and an
M.D. from the University of
Texas, where he was honored
by Alpha Omega Alpha when
he received the Student Re
search Award in 1968 and 1969.
Whiteside is a member of 16
medical associations and is
also editor of Clinical artho
pedic and Relnted Research and

The lourrull ofArthroplasty.

~

Medical Center Alumni
Association
Box 8049
660 S. Euclid
St. Louis, MO 63110

William Kaufman, Ph.D.,
M.D., FHS, of Stratford, Con
necticut, presented his paper
"Niacinamide Improves
Mobility in Degenerative Joint
Disease" before the Bio
chemistry and Pharmacology
Section of the 152nd Annual
Meeting of the American

~

Donald Sessions, M.D. '62
PresidclII
Jack Siefkas, Director
Medical Alumni and Development
Programs

Kellie Semler, Director
Medical Alumni Programs

Ruth Moenster
Secretary
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Patricia Newt
gres
atricia A. Newton, M.D. '75, travels
through life with giant strides that
would make Paul Bunyan proud.
At the age of 40, this Baltimore psychiatrist
has already packed more into her career
than most people would by retirement.
"I knew when I was 8 that I wanted to go
into medicine," she says. "They gave me a
nurse's cape, but I didn't want that.
I wanted a black bag with a stethoscope
in it."
None of Pat Newton's progress could sur
prise those who knew her as the spirited,
high-achieving, determined and somewhat
unorthodox daughter of scholar-educators
in her native Tuckerman , Ark. After aU ,
this is the young woman who as a child
broke a gi ft doll because she preferred
cowboy guns.
The diminutive doctor-to-be won a third
degree black belt in karate, went in for
weight lifting and aerobics, excelled in
Spanish and piano, hated math, played bas
ketball as a 5 ' 2/1 forward, became the only
pre-med member of the school touring choir
and refused to leave that group, even though
a faculty member worried that she was
trying to do too much.
Always an excellent student, she gradu
ated from high school at 15 - just as her
mother, then living in St. Louis, had done
20 years earlier. Before entering medical
school , she obtained her bachelor of science
degree in pre-medicine from the University

Patricia Newton, who graduated from the
School ofMedicine ill 1975, is now presi
dent ofan international behavioral science
management ronsultingfirm in Baltimore,
and assistant professor ofpsychiatry at
Johns Hopkins University.
of Arkansas in Pine Bluff, and graduated
magna cWlllaude from VanderbiJt Univer
sity with her master's in molecular biology.
While still in school, she worked as a
microbiologist for the state of Tennessee.
After receiving her medical degree,
she became a resident in psychiatry, then
chief resident and instructor in clinical psy
chiatry at Washington University School
of Medicine.

Her next stop was Baltimore, where she
took a second master's degree, this one in
public health from Johns Hopkins School of
Hygiene and Public Health. She then joined
the staff of Provident Hospital where, as
psychiatrist-in-chief, she instituted pioneer
programs for the rehabilitation of the
chronically mentally ill. She spurred the
hospital's sponsorship, together with the
National Institute of Mental Health, of the
first Baltimore International Congress of
Transcultural Psychiatry. The Congress
brought exchange scientists from all over
the world, more than 600 participants from
25 nations.
Newton has resigned that hospital POSt to
concentrate on her other professional inter
ests, but she remains an innovative leader
in the mental health area. President and
medical director of Behavioral Medicine
Associates, Inc. in Baltimore, she is editor
of that organization's health information and
educational service, president of Newton
THOTH, Inc., an international behavioral
science management consultant firm, and
on the faculty of Johns Hopkins University
as assistant professor of psychiatry.
Her research centers on the effects of
medical e.lectrical acupuncture in stress
management and in chronic pain.
Honor has followed closely on the
heels of achievement. As a distinguished
Marylander in medical science, she was
appointed to the Governor's Task Force on
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Alzheimer's Disease in Maryland and to the
State Advisory Council on Mental Hygiene.
In 1983, Baltimore Magazine cited her as one
of the city's "100 most intluential women."
Essellce, the nation's only black women's
litestyle magazine, chose her as "Woman of
the Year in Health and Medicine" in 1985 in
commemoration of the 15th anniversary of
the publication honoring black women who
have made outstanding contributions to
American society.
A love of scholarship and education,
in whatever field, was as much a part of
her heritage as is her name. Her father,
McKinley Newton, was her high school
principal in Tuckerman; her mother, tbe
former Bernice lones, was on the faculty
and coached basketball. They now live in
Little Rock, where her father is vice chan
cellor of Philander Smith College. Both are
graduates of Pat's alma mater in Pine Bluff.
"I studied science and math with Dad
and English with Mother. She was one of
the pioneer women's basketball coaches.
It was tough having her as a coach. I didn't
get any breaks," says Newton.
In Newton's high school days in Arkan
sas, she developed a special interest in
drama and later parlayed that interest into a
theater group for her patients.
"This started when I was head of psy
chiatry at Provident. We were looking for a
way to give chronically mentally ill patients
a way of rehabilitation.
"While I was lecturing at the University
of West Indies, I ran across a doctor who
was director of the lamaican Psychiatric
Services. He had trained in Edinburgh
and had begun to rehabilitate chronic pa
tients using the European technique called
sociodrama. "
Adapting the technique to her own hospi
tal population, she developed a highly suc
cessful program for her patients: "They
toured the area and played at lohns Hopkins
and several other hospitals. They developed
their own bank account and a couple of
them got jobs in theater arts, on stage crews
and similar work .
"This takes the chronically ill patients,
gets them out of the regressive arena so they
are able to interact and socialize and go out
and get jobs. It's a form of social reinte
gration, helping to prevent relapse because

they can better manage and manipulate
their environments.
"It was not a substitute for medication. It
was run as an adjunct to help people re
socialize. From that group we developed a
research program to carry those people for
ward. The state of Maryland developed
something called psychosocial rehabilitation
incJudingjob training for the mentally ill,
and this patient group had all the skills to
take full advantage of that program," ex
plains Newton.
Even though her work with the chroni
cally mentally ill sparks a missionary zeal,
Newton also is concerned with those who

are not so disabled enough to be institution
alized but who are, nevertheless, buffeted
by the tensions of modern society.
"(.n my private practice, we have a multi
specialty, doing a lot of prevention such as
stress reduction, weight control and smok
ing cessation. We still treat the typical
psychiatric patient, but my whole emphasis
is on behavioral change and prevention ."
One of her greatest concerns - even
though she is unmarried with no children
of her own - is the problem of youth
su icide, a symptom of society's late 20th
century ills.
"Generations ago, there were not so
many drugs available, not as much disin
tegration of the family," she says, as she
considers the causes of human stress.
"There is so much more divorce today,
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more single parents, and a lot more for chil
dren to get exposed to. We have a society
that believes in instant gratification. We
have a lot more violence, more child abuse,
spouse abuse, teenage pregnancies - and
suicide. According to the Youth Suicide
Prevention National Committee, 500,000
persons between the ages of 15 and 24 try to
kill themselves every year; 5,000 succeed."
Is there a cure, or, at least, a palliative?
Her answer comes swiftly. "It has to start
with re-education. I think it's too late for
many of our children. I think we will have
to change the structure of education .
"Children are having to make adult deci
sions long before they have adult mentality.
They are exposed to material things without
any kind of value system. Coupled with
that is the threat of the present competitive
environment. lobs are being taken away.
People are getting out of school while func
tionally illiterate."
The answer, she says, "should come from
the family, but the family isn't there any
more. The only other place is the school
system and groups of parents lending a
hand in some kind of collective support sys
tem. If we don't do something, we will have
a society of animals. None of us will be
sate."
How does she maintain her own sanity?
And how can others? "First of all," she says
with a laugh , "I thank God for good genes.
I was fortunate enough to have parents
who were not overly protective but did pro
tect me from certain things. I had a good
family support system that was caring and
loving and believed in allowing children to
develop normally.
"The other side of this is that I have seen
every kind of bad human behavior, and it all
comes to a very common denominator
many of these people are not loved and
nurtured."
She stresses the importance of "having
the nurturance of good friends and family
and the sanity to know that when things are
overwhelming, you can give them up. And,
remember, a little cry never hurts. We have
to accept our own limitations and be able to
let go and move on to the next level without
feeling guilty about it. Only God is per
fect. "
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A chance to conduct research under the direction ofintenzat iollally recog
nized scientists can help undergraduates make career choices and entice
them to select Washington Uni.'ersity for graduate study. See story. page 22.
~
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During orielltntwn week, this year's 120 freshmen JuuJ a chance to get
acquainted at a buffet supper at St. Charles Wine Gardell. The annual
freshmen welcoming party, which is sponsored by Washington University
Medical Center Alumni Associatwn,Jollows a bus tour ofSt. Louis.
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